Search Results

Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the development of a DNA-based vaccine using its PLACCINE platform technology.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three and six months ended June 30, 2022.

Celsion Corporation today announced financial results for the year ended December 31, 2021, and provided an update.

Celsion Corporation, a clinical-stage drug development company announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference.

Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, provided an update on the progress made in the Company’s two lead development programs.

Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options (the “Inducement Option Grants”) to purchase a total of 177,000 shares of common stock, and (ii) restricted stock grants.

Celsion Corporation today announced the company reported a cash position of $56.9 million as of December 31, 2021 during its earnings announcement on March 31, 2022.

Celsion Corporation announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs.

Celsion Corporation and Hainan Poly Pharm Co. Ltd. announced an amendment to their existing contract manufacturing agreement to include development work for Celsion’s investigational DNA-based COVID-19 vaccine.